Insider and congress filings
Edwards Lifesciences Corporation (EW)
About Edwards Lifesciences Corporation
from the company's filings and listing- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical - Devices
- Chief executive
- Bernard J. Zovighian
- Employees
- 16,000
- Listed since
- Mar 27, 2000
- Market value
- $49.6B
- Price to earnings
- 49.5
- Earnings per share
- $1.74
- Dividend yield
- -
Earnings
6 reported quarters · next on Oct 29, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Jul 23, 2026 | $0.78 | $0.74 | $1.7B | $1.7B | EPS beatRevenue beat |
| Apr 23, 2026 | $0.78 | $0.73 | $1.6B | $1.6B | EPS beatRevenue beat |
| Feb 10, 2026 | $0.58 | $0.62 | $1.6B | $1.5B | EPS missRevenue in line |
| Q3 FY2025reported Oct 30, 2025 | $0.67 | $0.60 | $1.6B | $1.5B | EPS beatRevenue beat |
| Jul 24, 2025 | $0.67 | $0.62 | $1.5B | $1.5B | EPS beatRevenue beat |
| Apr 23, 2025 | $0.64 | $0.60 | $1.4B | $1.4B | EPS beatRevenue in line |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for 2025 · proxy filed Mar 26, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Mr. ZovighianChief Executive Officer and Director | $1.2M | $7.2M | $9.1M | $17.5M |
| Mr. UllemCorporate Vice President, Chief Financial Officer | $808K | $2.2M | $3.0M | $6.1M |
| Mr. ChopraCorporate Vice President, Transcatheter Mitral and Tri | $671K | $1.8M | $2.3M | $4.7M |
| Mr. BoboCorporate Vice President, Strategy & Corporate Develop | $760K | $1.4M | $2.1M | $4.2M |
| Ms. BrülsCorporate Vice President, EMEACLA | $727K | $1.0M | $2.0M | $3.7M |
The summary compensation table from the 2025 proxy statement, current executives only. 1 executive who has since left the company is named in that filing and not shown here. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| Blackrock, Inc. | $5.3B | 58,789,433 | +11.8% | 10.20% |
| Vanguard Capital Management LLC | $3.4B | 37,615,952 | -0.3% | 6.53% |
| Vanguard Portfolio Management LLC | $2.4B | 26,411,402 | +0.0% | 4.58% |
| State Street Corp | $2.4B | 26,321,940 | +0.1% | 4.57% |
| Jpmorgan Chase & Co | $2.1B | 22,783,175 | +4.8% | 3.95% |
| Wellington Management Group LLP | $1.5B | 16,827,967 | -23.5% | 2.92% |
| Geode Capital Management, LLC | $1.4B | 15,437,251 | +17.5% | 2.68% |
| Bank Of New York Mellon Corp | $1.3B | 14,084,483 | -15.9% | 2.44% |
| DZ Bank AG Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main | $1.2B | 13,002,965 | +1.5% | 2.26% |
| Ninety One Uk Ltd | $1.1B | 12,337,502 | -0.5% | 2.14% |
| Aristotle Capital Management, LLC | $783.9M | 8,665,712 | +100.0% | 1.50% |
| FMR LLC | $763.1M | 8,435,949 | -41.8% | 1.46% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Open-market insider trades
18 filings of 306 on record| Insider | Action | Shares | Price | Value | Trade date | Delay |
|---|---|---|---|---|---|---|
| Andrew M. DahlSVP, Corporate Controller | Sold | 544 | $91.06 | $50K | Aug 31, 2026 | 0d |
| Annette BrulsCvp, Emeacla | Sold | 2,644 | $89.98 | $238K | Aug 28, 2026 | 0d |
| Daveen ChopraCvp, Tmtt, Surgical & Ihfm | Sold · 2 lines | 31,800 | $91.02 | $2.9M | Aug 26, 2026 | 0d |
| Wayne MarkowitzCvp, Japac | Sold | 1,240 | $91.47 | $113K | Aug 26, 2026 | 0d |
| Daniel J. LippisCvp, Tavr | Sold | 619 | $92.03 | $57K | Aug 11, 2026 | 0d |
| Wayne MarkowitzCvp, Japac | Sold | 146 | $86.03 | $13K | Jul 30, 2026 | 0d |
| Wayne MarkowitzCvp, Japac | Sold | 9,628 | $85.06 | $819K | Jul 28, 2026 | 0d |
| Bernard J. ZovighianCEO | Sold | 2,921 | $83.93 | $245K | Jul 27, 2026 | 0d |
| Daniel J. LippisCvp, Tavr | Sold | 619 | $91.70 | $57K | Jul 10, 2026 | 0d |
| Daniel J. LippisCvp, Tavr | Sold | 619 | $91.40 | $57K | Jun 30, 2026 | 0d |
| Bernard J. ZovighianCEO | Sold | 523 | $87.92 | $46K | Jun 17, 2026 | 0d |
| Andrew M. DahlSVP, Corporate Controller | Sold | 568 | $86.08 | $49K | May 29, 2026 | 0d |
| Donald E. Bobo Jr.Cvp,strategy/Corp Development | Sold | 23,145 | $86.42 | $2.0M | May 27, 2026 | 0d |
| Daveen ChopraCvp, Tmtt & Surgical | Sold | 1,500 | $84.60 | $127K | May 22, 2026 | 0d |
| Donald E. Bobo Jr.Cvp,strategy/Corp Development | Sold · 2 lines | 17,968 | $81.96 | $1.5M | May 15, 2026 | 3d |
| Daniel J. LippisCvp, Tavr | Sold | 620 | $81.14 | $50K | May 18, 2026 | 0d |
| Bernard J. ZovighianCEO | Sold · 2 lines | 36,351 | $77.93 | $2.8M | May 12, 2026 | 0d |
| Wayne MarkowitzCvp, Japac | Sold | 593 | $79.73 | $47K | May 11, 2026 | 0d |
One row is one filing. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count.
Congress trades in EW
20 disclosures of 96 on record · median 30d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | -3.0%S&P +0.6% · vs S&P 500 -3.6% | Aug 3, 2026 | Sep 4, 2026 | 32d |
| Alan ArmstrongSelfFiled late | Stock | Purchase | $1,001 - $15,000 | +8.6%S&P +20.2% · vs S&P 500 -11.6% | Mar 27, 2026 | Jul 21, 2026 | 116d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +5.9%S&P +3.2% · vs S&P 500 +2.7% | May 15, 2026 | Jun 9, 2026 | 25d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +2.6%S&P +5.8% · vs S&P 500 -3.2% | May 1, 2026 | Jun 9, 2026 | 39d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | -0.4%S&P +1.6% · vs S&P 500 -2.0% | May 27, 2026 | Jun 9, 2026 | 13d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +11.0%S&P +11.6% · vs S&P 500 -0.6% | Apr 13, 2026 | May 11, 2026 | 28d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +3.1%S&P +7.3% · vs S&P 500 -4.2% | Apr 24, 2026 | May 11, 2026 | 17d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +8.4%S&P +20.7% · vs S&P 500 -12.2% | Mar 30, 2026 | Apr 7, 2026 | 8d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +5.1%S&P +16.0% · vs S&P 500 -10.9% | Mar 23, 2026 | Apr 7, 2026 | 15d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +10.4%S&P +12.5% · vs S&P 500 -2.1% | Feb 5, 2026 | Mar 9, 2026 | 32d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | +0.2%S&P +15.1% · vs S&P 500 -14.9% | Nov 19, 2025 | Dec 29, 2025 | 40d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +12.3%S&P +13.9% · vs S&P 500 -1.6% | Oct 7, 2025 | Nov 6, 2025 | 30d |
| Jefferson Shreve | Stock | Sale | $50,001 - $100,000 | +15.2%S&P +30.8% · vs S&P 500 -15.6% | May 12, 2025 | Jun 22, 2025 | 41d |
| Bruce Westerman | Stock | Sale | $1,001 - $15,000 | +24.5%S&P +48.4% · vs S&P 500 -23.8% | Apr 21, 2025 | May 12, 2025 | 21d |
| Robert Bresnahan | Stock | Purchase | $1,001 - $15,000 | +29.3%S&P +54.2% · vs S&P 500 -24.8% | Apr 8, 2025 | May 8, 2025 | 30d |
| Jefferson Shreve | Stock | Purchase | $15,001 - $50,000 | +24.9%S&P +51.2% · vs S&P 500 -26.3% | Apr 7, 2025 | May 8, 2025 | 31d |
| Bruce Westerman | Stock | Purchase | $1,001 - $15,000 | +20.7%S&P +30.5% · vs S&P 500 -9.8% | Mar 3, 2025 | Apr 16, 2025 | 44d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +25.8%S&P +36.4% · vs S&P 500 -10.6% | Mar 12, 2025 | Apr 10, 2025 | 29d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +31.0%S&P +27.7% · vs S&P 500 +3.2% | Nov 12, 2024 | Dec 5, 2024 | 23d |
| Byron DonaldsFiled late | Stock | Sale | $1,001 - $15,000 | +24.8%S&P +78.9% · vs S&P 500 -54.1% | Oct 19, 2023 | Nov 8, 2024 | 386d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Members of Congress reporting a position
2 members · estimate, as of Sep 10, 20262 members report a position (estimated). The largest estimated position is in the $15,001 - $50,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| Julie Johnson | Democrat · House | $15,001 - $50,000 | 0.2% |
| Gilbert Ray Cisneros, Jr. | Democrat · House | $1,001 - $15,000 | <0.1% |
Estimate, as of Sep 10, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Awards, option exercises and gifts (20)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Daveen ChopraCvp, Tmtt, Surgical & Ihfm | Option exercise | 31,800 | Aug 26, 2026 |
| Daniel J. LippisCvp, Tavr | Option exercise | 619 | Aug 11, 2026 |
| Wayne MarkowitzCvp, Japac | Option exercise | 9,628 | Jul 28, 2026 |
| Bernard J. ZovighianCEO | Gift | 320 | Jul 27, 2026 |
| Annette BrulsCvp, Emeacla | Tax withholding | 109 | Jul 11, 2026 |
| Theodora MistrasCvp, Chief Financial Officer | Stock award | 161,720 | Jul 9, 2026 |
| Daniel J. LippisCvp, Tavr | Option exercise | 619 | Jul 10, 2026 |
| Daniel J. LippisCvp, Tavr | Tax withholding | 377 | Jul 7, 2026 |
| Daniel J. LippisCvp, Tavr | Option exercise | 619 | Jun 30, 2026 |
| Daniel J. LippisCvp, Tavr | Option exercise | 620 | May 18, 2026 |
| Bernard J. ZovighianCEO | Gift | 26,640 | May 12, 2026 |
| Bernard J. ZovighianCEO | Option exercise | 47,207 | May 11, 2026 |
| Daveen ChopraCvp, Tmtt & Surgical | Tax withholding | 7,538 | May 11, 2026 |
| Daveen ChopraCvp, Tmtt & Surgical | Option exercise | 13,583 | May 11, 2026 |
| Donald E. Bobo Jr.Cvp,strategy/Corp Development | Tax withholding | 7,469 | May 11, 2026 |
| Donald E. Bobo Jr.Cvp,strategy/Corp Development | Option exercise | 13,457 | May 11, 2026 |
| Bernard J. ZovighianCEO | Tax withholding | 26,198 | May 11, 2026 |
| Wayne MarkowitzCvp, Japac | Tax withholding | 226 | May 8, 2026 |
| Daniel J. LippisCvp, Tavr | Tax withholding | 362 | May 11, 2026 |
| Bernard J. ZovighianCEO | Gift | 5,489 | May 11, 2026 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Questions
Are insiders buying or selling EW?
Across the 18 most recent open-market filings shown here, 0 were purchases and 18 were sales.
Which members of Congress have traded EW?
Ro Khanna, Alan Armstrong, Josh Gottheimer, Jefferson Shreve, Bruce Westerman, Robert Bresnahan and others disclosed EW transactions in the filings shown here.
Which members of Congress hold EW?
2 members of Congress report a position in EW in the estimate we hold as of Sep 10, 2026. The two largest estimated positions belong to Julie Johnson and Gilbert Ray Cisneros, Jr.. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
Is EW in the S&P 500 or the Nasdaq 100?
Edwards Lifesciences Corporation is a current member of the S&P 500, per the membership list we hold as of Sep 10, 2026. Current members of either index get a page here whatever their filing history.
How quickly are EW trades disclosed?
Insider filings on this page reached the public a median of 0 days after the transaction, against the two business days Form 4 allows. Congressional disclosures took a median of 30 days, against the 45 the STOCK Act allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.